Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
Anita BoyapatiSergio SchwartzmanJérôme MsihidErnest ChoyMark C GenoveseGerd R BurmesterGordon LamToshio KimuraJonathan SadehDavid M WeinreichGeorge D YancopoulosNeil M H GrahamPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
IL-6 may be a prognostic marker of disease progression and severity, and patients with high IL-6 levels may be likely to benefit from sarilumab compared to adalimumab or MTX. Prospective validation is warranted to confirm the results of these post hoc analyses.